Compare Pfizer Inc (PFE) vs TKO Group Holdings Inc (TKO) Price & Performance

Pfizer (PFE) trades at $24.83, up 0.32% today, with a neutral technical signal and bearish moving averages. The company reported revenue of $62.58B in 2025, with a net income margin of 11.83%, and has beaten EPS estimates for the last three quarters. Recent news highlights pipeline developments in oncology and obesity, with a consensus analyst price target of $28.25.

PFE offers a stable dividend and trades below analyst targets, but faces headwinds from patent expirations and volatile cash flows. The stock presents value with a P/E of 19.04, though growth depends on successful drug launches and navigating post-COVID revenue normalization.

TKO trades at $182.79, down 1.26% on the day, with a bearish technical signal from moving averages. The stock shows strong analyst support with 89% buy ratings and a consensus price target of $228.40. Recent financials indicate revenue growth to $5.1B in 2026 with a net income margin of 4.47%, though valuation ratios like a P/E of 67.95 appear elevated. Key developments include a completed $800 million share repurchase and strong UFC event viewership.

The outlook for TKO is positive based on robust analyst consensus and expanding monetization from media deals, but risks include high valuation and recent insider selling. Earnings momentum needs to justify premium multiples, with the next quarterly report on August 3, 2026, critical for confirming growth trajectory.